scispace - formally typeset
S

Saraswati Sukumar

Researcher at Johns Hopkins University School of Medicine

Publications -  262
Citations -  28255

Saraswati Sukumar is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 77, co-authored 248 publications receiving 26027 citations. Previous affiliations of Saraswati Sukumar include Tufts University & Salk Institute for Biological Studies.

Papers
More filters
Journal ArticleDOI

HOX Genes: Major Actors in Resistance to Selective Endocrine Response Modifiers

TL;DR: Recent progress in understanding of the functioning of HOX genes and regulation of their expression by hormones is reviewed and the contributions of several members of the HOX gene family to endocrine resistant breast cancer are discussed.
Journal ArticleDOI

Tissue specific DNA methylation in normal human breast epithelium and in breast cancer.

TL;DR: Interestingly, TRIM29 regulation in breast tumors clustered according to the PAM50 classification, and was repressed in the estrogen receptor positive tumors, particularly in the more proliferative luminal B subtype.
Journal ArticleDOI

Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer

TL;DR: It is shown that the therapeutic efficacy of intraductal 225Ac-trastuzumab in a DCIS model of human SUM225 cancer cells in NSG mice was significantly higher than intravenous administration, with no kidney toxicity or loss of body weight.
Journal ArticleDOI

Molecular cloning and chromosomal localization of Chinese hamster telomeric protein chTRF1. Its potential role in chromosomal instability

TL;DR: These studies suggest that chTRF1 does not bind the interstitial telomeric repeats, and its presence at the metaphase chromosome ends is limited, which could be a factor contributing to frequent karyotypic alterations observed in Chinese hamster cells.
Journal ArticleDOI

Improvement of stability and efficacy of C16Y therapeutic peptide via molecular self-assembly into tumor-responsive nanoformulation

TL;DR: For the first time, it is demonstrated that a simple nanoformulation using a functional antitumor peptide as the building block can show innate antitumors activity and also provide a nanoplatform for combination therapy, opening a new avenue for the design of antitUMor nanotherapeutics.